

Declaration of Interests Register

Technology Appraisal Committee A

Publication Date: 06/03/2019

Topic: Benralizumab for treating severe eosinophilic asthma [1129] TA565

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Shuaib Nasser	Clinical Expert	Direct financial	Advisory boards for Novartis, GlaxoSmithKline and TEVA. Lectures for AstraZeneca and Novartis. Also undertaken clinical trials for AstraZeneca for benralizumab and for GlaxoSmithKline for mepolizumab and received no direct payment for these.		April 2018	Ongoing	Declare and participate. Not involved in decision making. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Prof Tim Harrison	Clinical Expert	Direct financial	Advisory boards for AstraZeneca relating to benralizumab. His institution has received funds for research trials from AstraZeneca. Honorarium and expenses from AstraZeneca, Chiesi, GlaxoSmithKline and Ventura.		April 2018	Ongoing	Declare and participate. Not involved in decision making. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Dr Adel Mansur	Clinical Expert	Direct financial	Advisory boards, talks, educational programmes, and sponsorship for conferences for		September 2018	Ongoing	Declare and participate. Not involved in decision making. Agreed by: Dr Jane Adam, Chair

			pharmaceutical companies including AstraZeneca, GlaxoSmithKline, Novartis, NAPP, BI, TEVA and Chiesi.				Janet Robertson, Associate Director
John McMurray	Committee Member	Indirect	His employer has received funding from AstraZeneca for a trial in heart failure.		September 2018	Ongoing	Declare and participate. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Alice Turner	Committee Member	Direct non-financial professional and personal interest	Has an investigator initiated study (IIS) grant from AstraZeneca in COPD, which is for a non CTIMP trial. Has been local PI on a trial of benralizimab for COPD, although has no role in study oversight or management and will not be an author on manuscripts. Her employees received commercial fees for her team enrolling patients for the study.	2015	November 2018	IIS grant ongoing, trial ceased 2017	Excluded from meeting. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.